From: Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach
Sets
Groups
Sensitivity
Specificity
Training set
33cases/33 controls
100% (33/33)
93.94% (31/33)
Testing set
48cases/33 controls
100% (48/48)
96.97% (32/33)